IDE397 is a potential first-in-class, orally bioavailable MAT2A inhibitor in clinical development for MTAP-deletion solid tumors. Ongoing development includes Phase 2 monotherapy expansion and combination studies. It is currently an investigational oncology candidate.
IDEAYA Biosciences announced Q4 2025 financial results with $1.05 billion in cash reserves and confirmed 130 progression-free survival events in its Phase 2/3 OptimUM-02 trial of darovasertib for metastatic uveal melanoma, with topline results expected by late March 2026.
Edgewise Therapeutics and IDEAYA Biosciences released annual financial reports detailing clinical trial progress and strategic initiatives. Both companies are advancing multiple clinical-stage programs while managing significant operating expenses.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07277413 |
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT05975073 |
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors |
COMPLETED | PHASE1/PHASE2 |
| NCT04794699 |
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion |
ACTIVE_NOT_RECRUITING | PHASE1 |
